Pharmaceuticals, Biotechnology & Life Sciences

Incyte’s journey shows how a small‑molecule oncology firm balances FDA setbacks, EMA approvals and value‑based reimbursement to drive growth and manage cost risks.

Vertex’s Phase III kidney trial shows 35% proteinuria reduction, opening a low‑competition, high‑margin niche beyond cystic fibrosis and sparking a sharp share rally.

Zoetis’s $1.3 B Neogen genomics acquisition boosts precision veterinary medicine, enhancing diagnostics, reducing costs, and driving future growth.

Recordati’s 114k‑share buy‑back boosts EPS and signals confidence, while emerging neuro‑endocrine therapies promise growth—under value‑based reimbursement, RWE, and AI‑driven care.

Explore why Sartorius AG’s stock dipped yet remains resilient—healthy revenue, strategic bioprocessing upgrades, and a focus on regulatory compliance could fuel future gains.

Merck KGaA faces market volatility as a generic Mavenclad enters the U.S. market, challenging its MS therapy revenue while the company’s semiconductor division offers a potential hedge for investors.

FDA warning hits Novo Nordisk, but a new Hims & Hers partnership could drive $1.2 B in U.S. telehealth sales while offsetting looming patent cliffs.

Roche Holding AG’s 2026 AGM highlights Swiss R&D focus, new equity structure, dividend boost, and a clear plan to tackle patent cliffs while targeting M&A to stay pharma‑market‑leading.

Novartis’ 2025 dividend steadies Swiss market sentiment, proving why the blue‑chip pharma leader remains a resilient, growth‑oriented choice amid global volatility.

Lonza’s divestiture and ZYNTEGLO partnership boost its CDMO focus and gene‑therapy scale, promising higher margins, reliable supply, and safer, effective β‑thalassemia treatment.